Allworth Financial LP Grows Holdings in Pfizer Inc. (NYSE:PFE)

Allworth Financial LP raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 14.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 152,240 shares of the biopharmaceutical company's stock after buying an additional 19,308 shares during the period. Allworth Financial LP's holdings in Pfizer were worth $3,858,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at about $27,000. Gould Capital LLC grew its position in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the period. North Capital Inc. acquired a new stake in shares of Pfizer in the first quarter valued at about $28,000. Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer in the fourth quarter valued at about $30,000. Finally, Curio Wealth LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research analyst reports. Bank of America lifted their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. The Goldman Sachs Group boosted their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Leerink Partners lowered their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research report on Wednesday, April 30th. Morgan Stanley boosted their price target on shares of Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Finally, BMO Capital Markets lowered their price target on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Price Performance

Shares of PFE stock opened at $25.65 on Friday. The firm's 50-day moving average is $23.89 and its two-hundred day moving average is $24.80. The company has a market capitalization of $145.83 billion, a PE ratio of 18.59, a price-to-earnings-growth ratio of 0.94 and a beta of 0.58. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.82 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.71%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.